Aurobindo Pharma Limited received FDA approval for oral Mycophenolate Mofetil tablets, a key asset in the chronic immunosuppressant market. The launch of this generic is expected to broaden the company's product portfolio and drive incremental revenue growth in the fourth quarter and beyond.